{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-029847","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.583857+00:00","generated_at":"2026-05-17T05:40:15.836868+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Moleculin gets Canadian patent allowance for Annamycin manufacturing process; term to 2040","bullets":["CIPO issued notice of allowance for patent application 3,142,510 covering preliposomal Annamycin lyophilizate preparation.","Patent expected to issue in coming months; base term extends to June 2040, subject to regulatory extension.","Company already holds issued U.S. and allowed European patents for Annamycin; additional applications pending globally.","CEO states this strengthens global IP portfolio for Annamycin as a non-cardiotoxic anthracycline for AML and STS lung mets."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-029847","json":"https://secwatch.observer/filing/0001437749-25-029847.json","markdown":"https://secwatch.observer/filing/0001437749-25-029847.md","text":"https://secwatch.observer/filing/0001437749-25-029847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925029847/0001437749-25-029847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925029847/mbrx20250923_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:40:15.836868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}